MedTrace Logo

A Study of Bermekimab in Patients With Hidradenitis Suppurativa

NCT03512275 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2022-03-14

Study results available
· View outcomes & findings →

Summary

Phase 2 study of bermekimab in patients with moderate to severe Hidradenitis Suppurativa.

Conditions

Interventions

DRUG

Bermekimab Monoclonal Antibody 400 mg

subcutaneous injection

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-20
Primary Completion
2019-01-14
Completion
2019-01-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03512275 on ClinicalTrials.gov